Rhythm Biosciences Ltd (ASX: RHY) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Rhythm Biosciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$16.76 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
284.08 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-36.78%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Rhythm Biosciences Ltd (ASX: RHY)
Latest News
Share Market News
What is going on with the Rhythm (ASX:RHY) share price today?
Share Market News
The Rhythm (ASX:RHY) share price surges on cancer testing milestone
Share Market News
Which ASX healthcare shares saw the biggest gains in February?
Share Market News
What's happening with the Rhythm (ASX:RHY) share price today?
Share Market News
Why the Rhythm (ASX:RHY) share price again reached a new all-time record today
Share Market News
Here's why the Rhythm (ASX:RHY) share price hit an all-time high today
Share Market News
Rhythm Biosciences (ASX: RHY) share price soars 1300% in 6 months
Share Gainers
Here's why the Rhythm Bioscience (ASX:RHY) share price is up 15% to a record high
Share Market News
Why the Rhythm Biosciences (ASX:RHY) share price jumped over 600% this year
Share Market News
The Rhythm (ASX:RHY) share price is surging 5% higher today. Here's why.
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price rocketed 28% to a record high
Share Gainers
These small cap ASX shares delivered more than 100% returns in November
RHY ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
RHY Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 25 Jun 2025 | $0.06 | $0.00 | 0.00% | 511,027 | $0.06 | $0.06 | $0.06 |
| 24 Jun 2025 | $0.06 | $0.00 | 0.00% | 1,103,992 | $0.06 | $0.06 | $0.06 |
| 23 Jun 2025 | $0.06 | $0.00 | 0.00% | 339,372 | $0.06 | $0.06 | $0.06 |
| 20 Jun 2025 | $0.06 | $0.00 | 0.00% | 573,318 | $0.06 | $0.07 | $0.06 |
| 19 Jun 2025 | $0.07 | $0.01 | 16.67% | 436,097 | $0.06 | $0.07 | $0.06 |
| 18 Jun 2025 | $0.06 | $0.00 | 0.00% | 136,183 | $0.06 | $0.06 | $0.06 |
| 17 Jun 2025 | $0.06 | $0.00 | 0.00% | 533,192 | $0.06 | $0.06 | $0.06 |
| 16 Jun 2025 | $0.06 | $0.00 | 0.00% | 61,022 | $0.06 | $0.06 | $0.06 |
| 13 Jun 2025 | $0.06 | $0.00 | 0.00% | 196,507 | $0.06 | $0.06 | $0.06 |
| 12 Jun 2025 | $0.06 | $0.00 | 0.00% | 382,633 | $0.06 | $0.06 | $0.06 |
| 11 Jun 2025 | $0.06 | $0.00 | 0.00% | 173,677 | $0.06 | $0.06 | $0.06 |
| 10 Jun 2025 | $0.06 | $0.00 | 0.00% | 452,883 | $0.06 | $0.06 | $0.06 |
| 06 Jun 2025 | $0.06 | $0.00 | 0.00% | 64,239 | $0.06 | $0.06 | $0.06 |
| 05 Jun 2025 | $0.06 | $0.00 | 0.00% | 53,779 | $0.06 | $0.06 | $0.06 |
| 04 Jun 2025 | $0.06 | $0.00 | 0.00% | 269,207 | $0.06 | $0.06 | $0.06 |
| 03 Jun 2025 | $0.06 | $0.00 | 0.00% | 18,895 | $0.06 | $0.06 | $0.06 |
| 02 Jun 2025 | $0.06 | $0.00 | 0.00% | 235,041 | $0.06 | $0.06 | $0.06 |
| 30 May 2025 | $0.07 | $0.00 | 0.00% | 265,006 | $0.06 | $0.07 | $0.06 |
| 29 May 2025 | $0.07 | $0.00 | 0.00% | 121,153 | $0.07 | $0.07 | $0.07 |
| 28 May 2025 | $0.06 | $0.00 | 0.00% | 17,695 | $0.06 | $0.06 | $0.06 |
| 27 May 2025 | $0.07 | $0.00 | 0.00% | 453,736 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Jul 2024 | Otto Buttula | Expiry | 1,342,500 | $71,152 |
Options expired.
|
| 31 Jul 2024 | Louis (Lou) Panaccio | Expiry | 85,000 | $4,505 |
Options expired.
|
| 31 Jul 2024 | Trevor Lockett | Expiry | 252,000 | $13,356 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Otto Leslie Steven Buttula | Executive ChairmanExecutive Director | Oct 2019 |
Mr Buttula has had experience and success in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula's executive experience includes co-founder and CEO and Managing Director of IWL Ltd, an online financial services company that listed on the ASX in 1999. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Ltd.
|
| Dr David Atkins | Chief Executive OfficerManaging Director | May 2024 |
--
|
| Mr Gavin Fox-Smith | Non-Executive Director | Dec 2024 |
Mr Fox-Smith has been a leader and champion of Medical Technology across Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is advocate for Gender Equality and Indigenous Engagement. His career spans over 35 years, previously holding the position of Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices, Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum. Gavin is currently transitioning out of his executive CEO role at Omnigon, a private Australian company in the Ostomy Care market. He is currently, Chair of ANDHealth (Australias National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation. Gavin is a member of the Champions of Change Coalition STEM/Health group and serves as Ambassador for Rotary Oceania Medical Aid for Children (ROMAC).
|
| Ms Andrea Steele | Company SecretaryGeneral Counsel | Feb 2022 |
-
|
| Mr James Stephen Barrie | Joint Company Secretary | Dec 2023 |
-
|
| Andrea Steele | Company SecretaryGeneral Counsel |
-
|
|
| Guy Carisbrooke | Financial Controller |
-
|
|
| James Stephen Barrie | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Webinvest Pty Ltd | 22,479,168 | 9.04% |
| Newfound Investments Pty Ltd | 13,905,407 | 5.59% |
| Ferndale Securities Pty Ltd | 10,300,000 | 4.14% |
| HSBC Custody Nominees (Australia) Limited | 9,269,796 | 3.73% |
| Loumea Investment Pty Ltd | 8,052,520 | 3.24% |
| Northern Star Nominees Pty Ltd | 7,380,000 | 2.97% |
| Rojo Nero Capital Pty Ltd | 4,213,751 | 1.70% |
| Giokir Pty Ltd | 3,661,470 | 1.47% |
| Mr Hsien Michael Soo | 3,305,403 | 1.33% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 3,000,000 | 1.21% |
| DC & PC Holdings Pty Ltd | 2,688,156 | 1.08% |
| Commonwealth Scientific & Industrial Research Organisation | 2,500,000 | 1.01% |
| Ms Natalie Louise Patterson | 2,477,083 | 1.00% |
| E & W Nominee Pty Ltd | 2,207,941 | 0.89% |
| Mr Daniel Eddington & Mrs Julie Eddington | 2,123,532 | 0.85% |
| Mr Wei Feng & Mrs Jie Liu | 2,050,215 | 0.82% |
| Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison | 2,000,000 | 0.80% |
| Ardroy Securities Pty Ltd | 1,857,040 | 0.75% |
| BNP Paribas Nominees Pty Ltd ACF Clearstream | 1,775,214 | 0.71% |
| Mrs Linda Jane Lockett & Dr Trevor John Lockett | 1,678,300 | 0.68% |